14 research outputs found
Evaluating the potential for digital submission of expedited premarket safety reports to the FDA
No full textEvaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs
No full textEnrolling Adolescents in Disease/Target-Appropriate Adult Oncology Clinical Trials of Investigational Agents
No full textA phase I study of cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Children’s Oncology Group phase I consortium trial.
No full textDiscordance of MLL-rearranged (MLL-R) infant acute lymphoblastic leukemia in monozygotic twins with spontaneous clearance of preleukemic clone in unaffected twin
No full text
A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children\u27s Oncology Group.
No full textAssessing an ASCO Decision Aid for Improving the Accuracy and Attribution of Serious Adverse Event Reporting From Investigators to Sponsors
No full textVandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma
No full text
